This Review is part of a thematic series on **Biological Role of Senescence in Cardiovascular Disease**, which includes the following articles:

### Vascular Cell Senescence: Contribution to Atherosclerosis

### Telomere Biology and Cardiovascular Disease

### Mechanisms of Cardiovascular Disease in Accelerated Aging Syndromes

### Progenitor Cell Senescence

### Mechanisms Underlying Caloric Restriction, Lipid Metabolism, and Life Span Regulation

Issei Komuro, Guest Editor

---

**Vascular Cell Senescence**

**Contribution to Atherosclerosis**

Tohru Minamino, Issei Komuro

**Abstract**—Cardiologists and most physicians believe that aging is an independent risk factor for human atherosclerosis, whereas atherosclerosis is thought to be a characteristic feature of aging in humans by many gerontologists. Because atherosclerosis is among the age-associated changes that almost always escape the influence of natural selection in humans, it might be reasonable to regard atherosclerosis as a feature of aging. Accordingly, when we investigate the pathogenesis of human atherosclerosis, it may be more important to answer the question of how we age than what specifically promotes atherosclerosis. Recently, genetic analyses using various animal models have identified molecules that are crucial for aging. These include components of the DNA-repair system, the tumor suppressor pathway, the telomere maintenance system, the insulin/Akt pathway, and other metabolic pathways. Interestingly, most of the molecules that influence the phenotypic changes of aging also regulate cellular senescence, suggesting a causative link between cellular senescence and aging. For example, DNA-repair defects can cause phenotypic changes that resemble premature aging, and senescent cells that show DNA damage accumulate in the elderly. Excessive calorie intake can cause diabetes and hyperinsulinemia, whereas dysregulation of the insulin pathway has been shown to induce cellular senescence in vitro. Calorie restriction or a reduction of insulin signals extends the lifespan of various species and decreases biomarkers of cellular senescence in vivo. There is emerging evidence that cellular senescence contributes to the pathogenesis of human atherosclerosis. Senescent vascular cells accumulate in human atheroma tissues and exhibit various features of dysfunction. In this review, we examine the hypothesis that cellular senescence might contribute to atherosclerosis, which is a characteristic of aging in humans. *(Circ Res. 2007;100:15-26.)*

**Key Words:** p53 ■ insulin ■ diabetes ■ angiotensin II ■ telomere

---

Epidemiological studies have shown that age is the dominant risk factor for atherosclerotic cardiovascular diseases.\(^1\)\(^2\) The incidence and the prevalence of atherosclerotic diseases, including coronary heart disease and stroke, both increase with advancing age.\(^1\)\(^2\) However, the molecular mechanisms underlying the increased risk of such diseases that is conferred by aging remain unclear. For example, arterial stiffness increases with age because of structural changes of the arterial walls as well as endothelial dysfunction, but convincing molecular explanations for these age-associated alterations of vascular structure and function have not yet been reported. Because aging includes various biological phenomena, it is difficult to attribute age-related changes of the vasculature or the organism to a certain
molecule. Moreover, there are no accurate biomarkers for aging, which makes it problematic to study vascular aging.

Cellular senescence is originally described as the finite replicative lifespan of human somatic cells in culture. Senescent cells enter an irreversible growth arrest, exhibit a flattened and enlarged morphology, and express a different set of genes, including negative regulators of the cell cycle such as p53 and p16. These phenotypic changes of senescent cells are not observed in quiescent cells and have been implicated in aging and age-associated diseases. Primary cultured cells from patients with premature aging syndromes, such as Werner syndrome and Bloom syndrome, are known to have a shorter lifespan than cells from age-matched healthy persons, supporting the notion that cellular senescence is associated with aging. This hypothesis of cellular aging was first described by Hayflick in the 1960s. However, the role of cellular senescence in human atherosclerosis has not attracted much attention in the past, and controversy exists regarding the relationship between cellular senescence and age-related diseases.

Recently, some research groups, including ours, have reexamined the hypothesis that vascular cell senescence might contribute to the pathogenesis of age-associated vascular diseases such as atherosclerosis by using cellular senescence as a model of aging in vivo. This approach may allow us to identify important molecules and signaling pathways involved in vascular aging. Although atherosclerosis has been considered as a chronic inflammatory disease and a number of underlying mechanisms have been implicated, accumulating evidence has suggested a critical role of vascular cell senescence in atherogenesis. In the present review, we describe recent evidence that supports the hypothesis of cellular aging in the vasculature and discuss the potential of antisenescent therapy for treating human atherosclerosis.

**Does Vascular Cell Senescence Induce Vascular Dysfunction Associated With Aging?**

Age-associated changes of the blood vessels include a decrease in compliance and an increase of inflammation. It has also been reported that angiogenesis becomes impaired with advancing age and that aging decreases the antithrombotic properties of the endothelium. These changes of vascular structure and function have been suggested to have a role in the increased risk of atherosclerotic cardiovascular disease in the elderly. A number of studies have shown that many of the changes of senescent vascular cells are consistent with those seen in human atherosclerosis (Table in the online data supplement, available at http://circres.ahajournals.org), suggesting a critical role of cellular senescence in vascular pathophysiology. Both NO production and endothelial NO synthase activity are reduced in senescent human vascular endothelial cells. The increment of NO production in response to shear stress is also less in senescent vascular endothelial cells. Production of reactive oxygen species (ROS) is increased in senescent cells, leading to a decrease in the bioavailability of NO and increased formation of peroxynitrite. Furthermore, prostacyclin production shows a significant decrease, with in vitro aging of vascular endothelial cells, whereas production of thromboxane A2 and endothelin-1 is augmented. Finally, senescent vascular endothelial cells show the upregulation of plasminogen activator inhibitor-1. All of these changes are likely to be involved in the impairment of endothelium-dependent vasodilation, as well as the increased tendency for thrombogenesis that occur in human atherosclerosis.

The interaction between monocytes and vascular endothelial cells is enhanced by endothelial cell senescence, promoting atherogenesis. This change appears to be mediated by upregulation of adhesion molecules and proinflammatory cytokines, as well as through decreased production of NO by senescent endothelial cells. It has been reported that senescent endothelial cells show a reduced ability to form capillaries in vitro. Bone marrow--derived circulating endothelial progenitor cells (EPCs) are known to participate in postnatal neovascularization and vascular repair. The growth and function of cultured bone marrow--derived EPCs are impaired in patients with coronary artery disease and show a negative correlation with various risk factors for coronary atherosclerosis, including age. Thus, aging may promote the senescence of EPCs as well as vascular endothelial cells, resulting in a decline of angiogenesis and vascular healing.

There is also evidence indicating that senescence-associated functional changes occur in vascular smooth muscle cells (VSMCs). The in vitro response of VSMCs to NO and β-adrenoreceptor stimulation is decreased by aging, and such changes may contribute to impairment of endothelium-dependent (as well as endothelium-independent) vasodilation in the elderly. Production of elastase by senescent VSMCs is increased whereas expression of fibronectin is enhanced in senescent vascular endothelial cells, as seen in the arteries of the elderly, and such changes may be relevant to age-dependent modifications of the extracellular matrix. It has been reported that senescent fibroblasts are resistant to apoptosis. In contrast to fibroblasts, apoptosis is enhanced in senescent vascular endothelial cells, a change that may contribute to plaque erosion and thrombosis in human atherosclerosis. Circadian rhythms are regulated by a set of clock genes that form transcriptional feedback loops and generate circadian oscillation with a 24-hour cycle. The circadian rhythm of blood pressure is often impaired with advancing age, so that there is no decrease at night (non-dipper status), and this change is known to increase the risk of cardiovascular disease. A recent study showed that circadian expression of clock genes is impaired by cellular aging both in vitro and in vivo, suggesting that cellular senescence in peripheral tissues may underlie the mechanism by which aging impairs the entrainment of peripheral circadian rhythms.

**In Vivo Evidence of Vascular Cell Senescence**

Vascular cells derived from human atherosclerotic plaques showed impaired growth in vitro and undergo senescence earlier than cells from normal vessels. The histology of human atherosclerotic lesions has been extensively studied, and it has been demonstrated that these lesions contain endothelial cells and VSMCs that exhibit the morphological
features of senescence. These findings suggest the occurrence of cellular senescence in vivo. Primary cultured cells undergoing senescence in vitro show increased activity of β-galactosidase (β-gal) when assayed at pH 6, which is distinguishable from endogenous lysosomal β-gal activity, which can be detected at pH 4. The former type is known as senescence-associated (SA) β-gal activity and has been shown to correlate with cellular aging.

Fenton et al successfully detected SA β-gal–positive vascular cells in injured rabbit carotid arteries. With repeated endothelial denudation, the accumulation of SA β-gal–positive cells was markedly enhanced. SA β-gal–positive vascular cells have also been demonstrated in human atherosclerotic plaques obtained from the coronary arteries of patients with ischemic heart disease. These cells are predominately localized on the luminal surface of the plaque and have been identified as endothelial cells, whereas no SA β-gal–positive cells are observed in the internal mammary arteries of the same patients in whom atherosclerotic changes are minimal (Figure 1). In advanced plaques, however, SA β-gal–positive vascular cells are only detected in the intima and not in the media, which may be the result of extensive replication in these lesions, as observed in arteries subjected to double endothelial denudation. SA β-gal–positive cells in human atheroma show enhanced expression of p53 and p16. Because expression of these molecules is increased in senescent cells in vitro, these observations further suggest the in vivo occurrence of vascular cell senescence. These cells also exhibit various functional abnormalities, such as decreased expression of endothelial NO synthase and increased expression of proinflammatory molecules. Although SA β-gal activity may not be a strict biomarker of senescence, these findings suggest that cellular senescence may contribute to the pathogenesis of vascular aging.

Molecular Mechanism of Cellular Senescence

Over the past few decades, significant progress has been made in our understanding of the mechanisms underlying cellular senescence. One widely discussed hypothesis of senescence is the telomere hypothesis. Telomeres are non–nucleosomal DNA/protein complexes located at the ends of chromosomes that serve as protective caps and act as the substrate for specialized replication mechanisms. As a consequence of semiconservative DNA replication, the extreme terminals of the chromosomes are not duplicated completely, resulting in successive shortening of the telomeres with each cell division. Critical telomere shortening is thought to trigger the onset of cellular senescence. Thus, telomere shortening has been proposed to act as a mitotic clock that prevents unlimited proliferation of human somatic cells.

Telomerase is a ribonucleoprotein that adds telomeres to the ends of chromosomes using its RNA moiety as a template. Since early studies reported that telomerase activity was detected in cancer cells and stem cells but not in normal somatic cells, the idea emerged that telomerase activity might be essential for tumor growth and the self-renewal potential of stem cells. Increasing evidence has suggested that telomerase activity regulates cell proliferation in normal somatic cells by telomere lengthening or by telomere length-independent mechanisms. Human endothelial cells and VSMCs express telomerase activity, which is drastically activated by mitogenic stimuli via a protein kinase C–dependent pathway, but the activity declined with in vitro aging because of a decrease in expression of TERT, leading to telomere shortening and cellular senescence. Introduction of telomerase extends the lifespan of both endothelial cells and VSMCs, suggesting a critical role of telomere and telomerase in vascular cell senescence.

It is likely that excessively short telomeres are sensed by cells, resulting in a pathway being activated that leads to exit from the cell cycle. It is now apparent that cellular senescence can also be induced by various kinds of stress independently of the replicative age of a cell. Cells undergo senescence by DNA damage that is irreparable or threatens to overwhelm the DNA-repair machinery. Supraphysiological mitogenic signals that result from the overexpression of oncogenes also elicit senescence in many normal cells. Finally, cells can undergo senescence in response to epigenetic changes of chromatin organization that may alter the expression of protooncogenes or tumor suppressor genes. Thus, it is possible that atherogenic stimuli increase cell turnover at sites of atherosclerosis, thereby promoting telomere shortening and possibly also activating certain proliferative signals that may induce senescence independently of telomere shortening. Moreover, oxidative stress and DNA damage could increase vascular cell senescence and thus further promote atherosclerosis.

Although diverse stimuli can induce senescence, they appear to converge mainly on either or both of 2 pathways that establish and maintain the process of cellular senescence. These pathways are regulated by the tumor suppressor proteins p53 and pRb. Both proteins are transcriptional regulators, and each lies at the center of signaling pathways responsible for cell cycle regulation, DNA repair, and cell death, which involve a number of upstream regulators and downstream effectors. p53 is a crucial mediator of the cellular response to DNA damage, and it induces the cyclin-dependent inhibitor p21. Dysfunctional telomeres resemble damaged DNA and thus trigger a p53-dependent response. Recent studies have demonstrated that nuclear foci containing markers of double-strand DNA breaks form in cells with critically short or dysfunctional telomeres, and it has been shown that such telomere dysfunction–induced nuclear foci are increased in the fibroblasts of aging primates. The p53 pathway is also important for senescence occurring in re-
response to oncogenic stimuli such as activation of Ras.83–85 Oncogenic Ras may trigger a p53-dependent damage response by increasing the production of ROS, which are required for the mitogenic effects of Ras activation.22

p16 is a positive regulator of pRb and induced by a variety of stress stimuli, including the overexpression of oncogenes such as Ras.96 In some cells, p16 expression is silenced by the methylation of its promoter.87,88 and the senescence response depends primarily on the p53-dependent pathway in such cells. However, at least some cells (including vascular cells) show increased expression of p16 during replicative senescence.4,89 Loss of p16 combined with retention of the p53-dependent pathway predisposes mice to tumorigenesis.90 Overexpression of p16 has been shown to prevent the reversal of senescence caused by inactivation of p53.91 Thus, the p16/pRb pathway appears to provide a formidable barrier to cell proliferation that cannot be overcome by loss of p53. It has been reported that the p16/pRb pathway induces reorganization of chromatin and thus affects the expression of cell cycle regulators.92–94 Senescent cells develop dense foci of heterochromatin that repress the E2F target genes encoding positive cell cycle regulators in a pRb-dependent manner.92–94 Although the whole picture of cellular senescence regulated by cell cycle modulators is far from complete and the questions of how many subpathways are involved have not yet been fully addressed, it is generally suggested that senescence occurs via the p53 pathway in response to DNA damage and telomere dysfunction, whereas the p16/pRb pathway mediates senescence caused by oncogenic stimuli, chromatin disruption, and other cellular stresses.

**Telomere-Dependent Senescence Impairs Vascular Function**

There is evidence indicating that telomere shortening occurs in human vessels, and this may be related to age-associated vascular diseases. The telomere length in the endothelial cells of the abdominal aorta and iliac arteries shows a strong inverse correlation with age.70,95 Importantly, telomere shortening occurs faster in the endothelial cells of the iliac arteries compared with those of the internal mammary arteries.70 Thus, high levels of hemodynamic stress may enhance the rate of endothelial cell turnover in the iliac arteries compared with that in vessels subjected to low hemodynamic stress. Telomere shortening is also more advanced in coronary artery endothelial cells from patients with coronary heart disease compared with cells from healthy subjects.96

The telomere length of white blood cells from healthy subjects shows an inverse correlation with the pulse pressure that is independent of the chronological age, at least in men.97 In patients with severe coronary artery disease, the telomeres of white blood cells are significantly shorter than those of cells from controls, which might reflect accelerated biological aging of various tissues (including the coronary arteries).98 In fact, the risk of myocardial infarction is increased by approximately 2- to 3-fold in subjects with shorter telomeres.99 Shorter telomeres are associated with an increase of carotid atherosclerosis in hypertensive subjects,100 whereas degenerative aortic valve stenosis is correlated with telomere shortening in the elderly, and this correlation is independent of coronary heart disease.101 Short telomeres are also found in patients with vascular dementia.102 It has been reported that various risk factors for cardiovascular disease, such as obesity, smoking, psychological stress, insulin resistance, hypertension, and diabetes, are associated with lower telomerase activity or shortening of the telomeres in white blood cells.103–108 Cawthon et al.109 examined the telomere length in 143 normal unrelated subjects who were more than 60 years of age and found that those with shorter telomeres in their white blood cells had worse survival, which was attributable to a 3.18-fold higher mortality rate from heart disease and an 8.54-fold higher mortality rate from infections. In contrast, 2 recent studies demonstrated no association between telomere length and mortality in the elderly.110,111

It has been demonstrated that disturbance of telomere integrity leads to endothelial dysfunction in vitro.19 Telomerase-deficient mice have a normal phenotype in the first generation, presumably because mice possess very long telomeres.64,112 However, their telomeres become shorter with successive generations, and these mice become infertile by the sixth generation because of impairment of the reproductive system.64 Some of the changes in the later generations of these mice mimic age-associated phenomena. For example, these animals have a shortened lifespan and a reduced capacity to respond to stresses such as wounds and hematopoietic ablation.113 Neovascularization is also impaired in the later generations of telomerase-deficient mice.114 This decreased ability to form new vessels may be attributable to impairment of the function and replicative capacity of vascular endothelial cells induced by telomere shortening. In a mouse model of atherosclerosis, telomere shortening has been shown to decrease the area of atherosclerotic lesions, presumably because of reduced proliferation of macrophages.115 However, telomerase-deficient mice develop atherosclerotic plaques with a thin fibrous cap, suggesting that shortening of the telomeres in vascular cells may induce plaque rupture in human atherosclerosis. Mice lacking telomerase activity develop hypertension in the first and third generations as a result of an increase in plasma endothelin-1 levels caused by endothelin-converting enzyme overexpression.116 In the spontaneously hypertensive rats (SHRs), a widely used model of essential hypertension, vascular hypertrophy develops before there is significant elevation of the blood pressure, and is associated with an increase in both the number and size of VSMCs. In contrast to telomerase-deficient mice, Cao et al.117 demonstrated that telomerase activity was increased in the aortas of SHRs compared with normotensive control rats. This increase of activity was detected as early as 3 weeks after birth, which was well before the onset of hypertension. Likewise, telomerase activity was increased in injured arteries, and inhibition of the activity reduced intimal formation after injury, suggesting that increased telomerase activity promotes vascular remodeling and contributes to the elevation of blood pressure.67,118 Although telomerase-deficient mouse is not strictly a model of aging, further studies using this model will provide insights into the role of telomere and telomerase in vascular pathophysiology.
Angiotensin II Induces Premature Vascular Cell Senescence

Arterial components of the angiotensin II (Ang II) signaling cascade increase with aging and contribute to the pathogenesis of atherosclerosis, and inhibition of Ang II activity has been demonstrated to improve the morbidity and mortality of cardiovascular disease.\(^{1,15}\) Ang II signaling appears to play a critical role in regulating many of the stimuli and signals that govern vascular aging and atherogenesis. Recently, Ang II was reported to induce the premature senescence of human VSMCs via the p53/p21-dependent pathway.\(^{74}\) Inhibition of this pathway effectively suppresses the induction of pro-inflammatory cytokine production, as well as premature senescence, in VSMCs by Ang II. Ang II was also shown to increase the number of senescent VSMCs and induce the expression of pro-inflammatory molecules, as well as p21, in a mouse model of atherosclerosis.\(^{74}\) Loss of p21 markedly ameliorated the induction of proinflammatory molecules by Ang II, thereby preventing the development of atherosclerosis. Merched and Chan\(^{120}\) also reported that lack of p21 has a protective effect against atherosclerosis in fat-fed apolipoprotein E (apoE)-deficient mice.

p53 immunoreactivity is detectable in vascular cells from sites of chronic inflammation in human atheroma, whereas only a few cells are positive for p53 in control arteries.\(^{60,121}\) p21 immunoreactivity is also detected in human atheroma, but not in normal vessels, and it colocalizes with p53. The overexpression of cyclin-dependent kinase inhibitors induces premature senescence of cultured vascular cells that is associated with cellular dysfunction.\(^{74}\) These observations suggest a pathological role of p53 and p21 in atherogenesis. It has been demonstrated that atherosclerosis is aggravated in p53/ apoE double-knockout mice through an increase of p53-controlled proliferation.\(^{122}\) Moreover, apoE*3–Leiden transgenic mice, a variant of the apoE knockout mouse, undergo accelerated atherosclerosis after bone marrow reconstitution with p53-deficient marrow cells.\(^{123}\) In contrast, a study using a perivascular collar in apoE knockout mice shows that p53 overexpression resulted in a marked decrease of the cellular and extracellular contents of the cap region, leading to spontaneous plaque rupture,\(^{124}\) whereas p21 deficiency stabilized atherosclerotic plaques by inhibiting vascular inflammation and inducing VSMC growth to prevent plaque rupture.\(^{74}\) Thus, overexpression of p53 and p21 by vascular cells may have a deleterious effect in human atherosclerosis.

Ang II is an important molecule that activates the Ras signaling pathway. Consistent with the influence of Ang II on senescence, constitutive activation of Ras has been found to induce vascular cell senescence and is associated with vascular inflammation.\(^{60}\) Activation of Ras leads to a marked increase in the expression of proinflammatory cytokines by cultured vascular cells, which is partially mediated through extracellular signal-regulated kinase activation. Introduction of Ras into balloon-injured arteries enhances vascular inflammation, as well as cellular senescence, compared with the responses seen in control injured arteries. Moreover, senescent cells in human atherosclerotic plaque express inflammatory molecules, and extracellular signal-regulated kinase is activated in these cells, suggesting that a Ras-dependent mechanism may also contribute to vascular cell senescence in human atherosclerosis. Consistent with these findings, inhibition of Ras activity has been demonstrated to suppress the release of proinflammatory molecules, thereby reducing lesion formation in apolipoprotein E-deficient mice.\(^{125}\) Thus, the Ang II/Ras signaling pathway appears to promote atherogenesis in humans at least partially by inducing vascular cell senescence via the p53/p21 pathway.

Oxidative Stress, Mitochondria, and DNA Damage

Oxidative stress has been suggested to have a role in human aging as well as cellular senescence.\(^{126}\) Chronic oxidative stress caused by chemical oxidants induces telomere shortening and accelerates the onset of senescence,\(^{127}\) as well as senescence-associated death,\(^{25}\) in human endothelial cells. Homocysteine, which is among the risk factors for atherosclerosis, induces telomere shortening and accelerates endothelial cell senescence.\(^{128}\) Oxidized low-density lipoprotein is reported to inactivate telomerase by inhibiting the phosphoinositide 3-kinase/Akt pathway in vascular endothelial cells\(^{129}\) and induces premature senescence.\(^{130}\) Conversely, suppression of oxidative stress or hypoxia preserves telomere length and extends the lifespan of cells, at least partly through an increase of telomerase activity.\(^{23,68,111}\) NO also activates telomerase and delays the onset of endothelial cell senescence. It is possible that NO reacts with intracellular radicals and decreases oxidative stress, resulting in the activation of telomerase.\(^{132}\) Constitutive activation of the small GTPase rac-1 results in mitochondrial oxidative stress via the generation of ceramide and thus induces premature endothelial cell senescence.\(^{24}\) Ceramide also increases when endothelial cells undergo replicative senescence.\(^{47,133}\) Senescence-enhanced oxidative stress appears to be associated with decreased expression of mitochondrial cytochrome c oxidase by vascular endothelial cells.\(^{20,134}\) Altered expression of other mitochondrial genes has also been reported and may participate in endothelial cell senescence.\(^{135}\) Vascular endothelial cells cultured on a glycated type I collagen substrate undergo early senescence, and antioxidant treatment delays the onset of senescence,\(^{136}\) which may be related to the pathogenesis of diabetic vasculopathy. Asymmetrical dimethyl L-arginine (ADMA), an endogenous NO synthesis inhibitor, increases cellular ROS levels and accelerates endothelial cell senescence.\(^{137}\) Conversely, aspirin reduces the formation of ADMA, decreases ROS levels and increases NO production, thereby delaying the onset of endothelial cell senescence.\(^{138}\) Treatment with L-arginine effectively inhibits ADMA- or homocysteine-accelerated endothelial cell aging by increasing NO formation and consequently the induction of heme oxygenase-1.\(^{139}\) Induction of senescence-like phenotypic changes has been reported in vascular endothelial cells exposed to ionizing radiation.\(^{140}\)

The majority of ROS can be traced back to the mitochondria. The generation of mitochondrial ROS is a consequence of oxidative phosphorylation, a process that produces a potential energy for protons across the mitochondrial inner membrane. A number of studies have demonstrated that mitochondrial integrity declines with aging.\(^{141}\) It has been
also reported that point mutations or deletions of mitochondrial DNA progressively accumulate during human aging. This accumulation is postulated to lead to the promotion of mitochondrial dysfunction and the generation of ROS that, in turn, induces further mitochondrial DNA mutations. There is evidence suggesting the importance of mitochondrial dysfunction in cellular senescence. Increased ROS caused by mitochondrial dysfunction is thought to induce telomere shortening and accelerate the onset of senescence. Interestingly, vascular complications are commonly observed in young subjects with mitochondrial disease in the absence of risk factors for atherosclerosis. Indeed, mitochondrial DNA damage correlates with the extent of atherosclerosis, suggesting that mitochondrial dysfunction may promote atherogenesis by inducing vascular cell senescence.

Recently, Trifunovic et al have provided evidence that supports the mitochondrial DNA mutation theory for aging. They generated mitochondrial mutator mice that express a proof-reading–deficient version of mitochondrial DNA polymerase. These mice display a normal phenotype at birth and in early adolescence but subsequently acquire many features of premature aging. Conversely, overexpression of catalase in the mitochondria reduces oxidative damage, extends murine lifespan, and delays the onset of vascular aging. However, more recent studies have shown that mitochondrial DNA mutations cause aging phenotypes without affecting ROS production. Thus, a causal relationship between mitochondrial DNA mutations, oxidative stress, and vascular aging remains to be fully determined.

One of the cellular targets of ROS is DNA. Many different types of oxidative DNA lesions have been described, ranging from base modifications to single- and double-strand breaks. To cope with DNA damage, cells have evolved DNA-repair systems. Breaks that affect only 1 DNA strand are repaired via the processes of nucleotide-excision repair or base-excision repair, whereas double-strand breaks are repaired by homologous recombination or by nonhomologous recombination with end joining. Some mice that lack components of these DNA-repair systems exhibit the early onset of changes associated with aging, like their human counterparts and fibroblasts from these mice show accelerated senescence. Constitutive activation of p53 but not an increase of p53 activity mediated through an extra copy of the intact p53 gene causes premature aging that is characterized by a reduced lifespan, osteoporosis, organ atrophy, and diminished stress tolerance. More importantly, cellular senescence has been detected in vivo by studies of mice with premature aging. Thus, these results provide in vivo evidence linking cellular senescence to aging of the organism. However, there are no reports that mice with premature aging show accelerated atherosclerosis. Expression of p16 increases in almost all tissues with advancing age and is considered as a biomarker of aging. Recently, the separate groups examined its role in regeneration of 3 different tissues, the blood, pancreas, and brain, and found that p16 is not only a biomarker but an effector of aging. However, it remains unclear whether p16 contributes to the pathogenesis of vascular aging.

### Premature Aging Syndromes

Among the human progeroid syndromes, patients with Werner syndrome (WRN) or Hutchinson–Gilford progeria syndrome (HGPS) prematurely develop atherosclerosis and often die of myocardial infarction. The mutation causing WRN has been identified as affecting a member of the RecQ family of helicases. WRN helicase appears to be involved in DNA recombination, replication, repair, and transcription, as well as in maintaining telomere integrity. WRN-null mice develop normally and do not exhibit premature aging. In contrast, WRN-deficient mice that have shorter telomeres like humans show a variety of changes similar to those seen in WRN patients, suggesting that telomere attrition is a key element in the pathology of WRN. HGPS is referred to as “childhood progeria” to differentiate it from WRN, which is referred to as “adult progeria.” Patients with HGPS progressively develop atherosclerosis, and myocardial infarction or cerebrovascular events occur at an average age of 13 years. Mutations causing HGPS have been identified in the human nuclear lamin A gene. It has been suggested that accumulation of mutant lamin A causes progressive changes of nuclear architecture and epigenetic control of gene expression, thus inducing premature aging. Like WRN fibroblasts, cultured fibroblasts obtained from HGPS patients undergo early senescence. Thus, it is assumed that accelerated senescence of vascular cells may underlie the occurrence of premature atherosclerosis in these diseases. However, because the changes of vascular aging have not been described in the relevant mouse models, more studies are necessary to clarify our understanding of the mechanism of premature atherosclerosis.

### Vascular Cell Senescence in Diabetic Vasculopathy

Restriction of calorie intake is known to improve the longevity of organisms ranging from yeast to mice. Low calorie intake prevents various age-dependent changes, such as the development of cancer and atherosclerosis, the decline of immunity, and the increase of inflammatory parameters. Because the plasma levels of glucose, insulin, and insulin-like growth factor-1 are decreased by calorie restriction, changes of these pathways may underlie the improvement of longevity related to a lower calorie intake. Consistent with these observations, genetic analyses have demonstrated that reduction-of-function mutations of the signaling pathway for insulin/insulin-like growth factor-1/phosphatidylinositol 3-kinase/Akt extend the lifespan of the nematode Caenorhabditis elegans. The forkhead transcription factor, Daf-16, which is phosphorylated and inactivated by Akt, plays an essential role in this longevity pathway. Recently, it was reported that the genes regulating longevity are conserved in organisms ranging from yeast to mice (Figure 2). These mutations that extend the lifespan are associated with an increase in resistance to oxidative stress, which is partly mediated by the increased expression of antioxidant genes.

A more recent study demonstrated a critical role of the insulin/Akt signaling pathway in regulating the lifespan of primary cultured human endothelial cells in a similar manner to its control of the longevity of C. elegans (Figure 2).
Insulin resistance and hyperinsulinemia are essential to cellular senescence but also to vascular dysfunction, such as impaired endothelium-dependent relaxation and reduced angiogenesis, whereas treatment of these rats with antioxidants prevents endothelial senescence and ameliorates the above changes. Yokoi et al recently demonstrated that high glucose also induces endothelial cell senescence.192 Taken together, these findings suggest that diabetes promotes the senescence of EPCs as well as endothelial cells via the insulin/Akt pathway and/or the high glucose–induced signaling pathway, resulting in the development of diabetic vascular complications. Increased plasma and tissue levels of proinflammatory cytokines and prothrombogenic factors have been demonstrated to exacerbate insulin resistance and to contribute to diabetic complications,193,194 and both of these changes are well-known features of cells undergoing senescence in vitro.4 Accordingly, type 2 diabetes can be regarded as a premature aging syndrome in which the dysregulation of insulin/Akt signaling promotes cellular senescence and leads to various complications. This suggests that antisenescence therapy might be effective for the treatment of not only diabetic vasculopathy but also other complications and insulin resistance.

Conclusion

There is evidence for a critical role of cellular senescence in the process of aging and various age-related diseases, including atherosclerosis. Antisenescence therapy is now emerging as a novel strategy for the treatment of human atherosclerosis, and several target molecules could be considered. One candidate is telomerase. There have been a number of reports demonstrating that telomerase is activated by medications or humoral factors that are known to exert a beneficial effect on cardiovascular disease, such as statins,195 thiazolidinediones, aspirin,138 and estrogen.197 Ang II type 1 receptor antagonists may also be useful for the treatment of vascular aging by suppressing Ang II–induced senescence.74 p53 antagonists are available,198 but systemic inhibition of p53 activity may induce tumorigenesis. It has also been reported that calorie restriction extends the lifespan of yeasts by activating the nicotinamide-adenine dinucleotide–dependent histone deacetylase Sir2.199 Increased activity of sirtuins, its functional ortholog, has been shown to extend the lifespan of mammalian cells.200 Thus, calorie restriction mimetics including sirtuin activators201 may be among the best candidates for antisenescence therapy. Tissue-specific inhibition of the signaling pathways for senescence also increases antisenescence signals in a non–cell autonomous manner177,179,180,202 and has the potential to ameliorate age-
associated diseases such as atherosclerosis. Thus, the factors that mediate this intriguing mechanism may be another candidate for antisenescence therapy. Identification of such factors will help to provide new methods for the treatment of human atherosclerosis.

Sources of Funding
This work was supported by the Ministry of Education, Science, Sports, and Culture of Japan (a Grant-in-Aid for Scientific Research, Developmental Scientific Research, and Scientific Research on Priority Areas to I.K. and a Grant-in-Aid for Scientific Research to T.M.) and by grants from the NOVARTIS Foundation (to T.M.).

Disclosures
None.

References


Vascular Cell Senescence: Contribution to Atherosclerosis
Tohru Minamino and Issei Komuro

Circ Res. 2007;100:15-26
doi: 10.1161/01.RES.0000256837.40544.4a
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2007 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/100/1/15

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2007/01/04/100.1.15.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
### Supplementary Table

**Molecules that alter in expression, cellular levels, and activity associated with vascular cell senescence**

<table>
<thead>
<tr>
<th>Function</th>
<th>Molecule</th>
<th>Changes</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular tone</td>
<td>eNOS</td>
<td>Decrease</td>
<td>1-4</td>
</tr>
<tr>
<td></td>
<td>ROS</td>
<td>Increase</td>
<td>5-10</td>
</tr>
<tr>
<td></td>
<td>Endothelin-1</td>
<td>Increase</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>COX-2</td>
<td>Increase</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>TXA2</td>
<td>Increase</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>Prostacyclin</td>
<td>Decrease</td>
<td>13</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>PAI-1</td>
<td>Increase</td>
<td>12, 14, 15</td>
</tr>
<tr>
<td>Matrix</td>
<td>Elastase</td>
<td>Increase</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Fibronectin</td>
<td>Increase</td>
<td>17, 18</td>
</tr>
<tr>
<td></td>
<td>MMP-9</td>
<td>Increase</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>MMP-2</td>
<td>Increase</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>TGF-β2</td>
<td>Increase</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>β-IG-H3</td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>CHST3</td>
<td>Increase</td>
<td>23</td>
</tr>
<tr>
<td>Inflammation</td>
<td>ICAM-1</td>
<td>Increase</td>
<td>3, 21, 24, 25</td>
</tr>
<tr>
<td></td>
<td>IL-1</td>
<td>Increase</td>
<td>3, 12, 26, 27</td>
</tr>
<tr>
<td></td>
<td>IL-6</td>
<td>Increase</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>IL-8</td>
<td>Increase</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>MCP-1</td>
<td>Increase</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>Staf50</td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td>Mitochondria</td>
<td>CO</td>
<td>Decrease</td>
<td>5, 28</td>
</tr>
<tr>
<td></td>
<td>ND2</td>
<td>Increase</td>
<td>29</td>
</tr>
<tr>
<td><strong>Online Supplement</strong></td>
<td><strong>T Minamino et al.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Cellular senescence and atherosclerosis</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>ND3</strong></th>
<th>Increase</th>
<th>29</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ATPase 6</strong></td>
<td>Increase</td>
<td>29</td>
</tr>
<tr>
<td><strong>16S rRNA</strong></td>
<td>Increase</td>
<td>29</td>
</tr>
<tr>
<td><strong>Cell death</strong></td>
<td>Ceramide</td>
<td>Increase</td>
</tr>
<tr>
<td><strong>Caspase 3 activity</strong></td>
<td>Increase</td>
<td>4, 10, 32</td>
</tr>
<tr>
<td><strong>Bcl-2</strong></td>
<td>Decrease</td>
<td>32</td>
</tr>
<tr>
<td><strong>Bad</strong></td>
<td>Increase</td>
<td>32</td>
</tr>
<tr>
<td><strong>PIG3</strong></td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td><strong>Cell growth</strong></td>
<td><strong>EGF receptor</strong></td>
<td>Decrease</td>
</tr>
<tr>
<td><strong>PDGF receptor</strong></td>
<td>Decrease</td>
<td>34</td>
</tr>
<tr>
<td><strong>Telomerase activity</strong></td>
<td>Decrease</td>
<td>35-38</td>
</tr>
<tr>
<td><strong>TERT</strong></td>
<td>Decrease</td>
<td>38</td>
</tr>
<tr>
<td><strong>GADD153</strong></td>
<td>Increase</td>
<td>21</td>
</tr>
<tr>
<td><strong>SNEV</strong></td>
<td>Decrease</td>
<td>39</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td><strong>FABP</strong></td>
<td>Increase</td>
</tr>
<tr>
<td><strong>Thymosin β-10</strong></td>
<td>Decrease</td>
<td>41</td>
</tr>
<tr>
<td><strong>AP-1 activity</strong></td>
<td>Decrease</td>
<td>42</td>
</tr>
<tr>
<td><strong>Bmal-1</strong></td>
<td>Decrease</td>
<td>43</td>
</tr>
<tr>
<td><strong>IGFBP-3</strong></td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td><strong>IGFBP-5</strong></td>
<td>Increase</td>
<td>21</td>
</tr>
<tr>
<td><strong>Neurofilament subunit L</strong></td>
<td>Increase</td>
<td>21</td>
</tr>
<tr>
<td><strong>SEC13R</strong></td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td><strong>NSPL1</strong></td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td><strong>TAXREB107</strong></td>
<td>Increase</td>
<td>22</td>
</tr>
<tr>
<td><strong>Adenosin A2A receptor</strong></td>
<td>Increase</td>
<td>21</td>
</tr>
<tr>
<td><strong>KRT7</strong></td>
<td>Decrease</td>
<td>23</td>
</tr>
<tr>
<td><strong>GSTP1</strong></td>
<td>Increase</td>
<td>23</td>
</tr>
</tbody>
</table>
Calumenin Increase 23
RCN1 Increase 23
FBOX21 Decrease 23
eNOS, endothelial nitric oxide synthase; ROS, reactive oxygen species; COX-2, cyclooxygenase-2; TXA2, thromboxane A2; PAI-1, plasminogen activator inhibitor-1, MMP, matrix metalloprotease; TGF, transforming growth factor; β-IG-H3, TGF-β-inducible gene human 3; CHST3, carbohydrate sulfotransferase 3; ICAM-1, intracellular adhesion molecule-1; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; Staf50, stimulated transacting factor of 50 kD; CO, cytochrome c oxidase; ND, NADH dehydrogenase; rRNA, ribosomal RNA; PIG3, p53-inducible gene 3; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; TERT, telomerase reverse transcriptase; GADD, growth-arrest and DNA-damage inducible protein 153; SNEV, senescence evasion factor; FABP, fatty acid binding protein; Bmal, brain and muscle ARNT (aryl hydrocarbon receptor nuclear translocator)-like protein; IGFBP, insulin-like growth factor binding protein; SEC13R, a human gene SEC13R related to the yeast secretory pathway gene SEC13; NSPL1, neuroendocrine-specific protein-like protein 1; TAXREB107, HTLV-I Tax responsive element binding protein 107; KRT7, cytokeratin 7; GSTP1, glutathione S-transferase P1; RCN1, reticulocalbin 1; FBOX21, F-box only protein 21.

References


19. Moon SK, Cha BY, Kim CH. In vitro cellular aging is associated with enhanced


27. Minamino T, Yoshida T, Tateno K, Miyauchi H, Zou Y, Toko H, Komuro I. Ras


